Adenosine Receptor Antagonists
AssigneeSantaris Pharma A/S
InventorsJacob Ravn, Christoph Rosenbohm, Katrine Qvortrup, Troels Koch
Life of this patent
Estimating the term…
Loading patent…
AssigneeSantaris Pharma A/S
InventorsJacob Ravn, Christoph Rosenbohm, Katrine Qvortrup, Troels Koch
Estimating the term…
The present application discloses locked nucleoside compounds of the Formula I which act as antagonists of adenosine receptors, in particular the adenosine A3 receptor, and the use of such adenosine A3 receptor compounds in medicine, e.g. for the treatment or alleviation or prophylaxis of selected from the group consisting of pain; inflammatory diseases, arthritis, multiple sclerosis, inflammation, asthma and psoriasis; gastro-intestinal disorders; allergy; disorders associated with mast cell or eosinophil activation and degranulation; cardio-vascular disorders; cutaneous diseases; wound healing; opthalmological disorders; respiratory disorders; kidney diseases; central nervous system disorders; Alzheimer's disease, Creutzfeldt-Jacob disease, Huntington's disease and Parkinson's disease; trauma and seizure; diabetes; osteoporosis; diseases of the immune system; cancers, infections; high blood pressure, locomotor hyperactivity, hypertension and depression; acute hypoxia; neonatal hypoxia, hypoxia and chronic hypoxia; and infertility.
A compound of Formula I having the structure:
(canceled)
Dependencies are inferred from the claim text.